Why Voyager Technologies (VOYG) stock is up today: Wedbush Outperform call meets ISS drug-research deal
23 January 2026
1 min read

Why Voyager Technologies (VOYG) stock is up today: Wedbush Outperform call meets ISS drug-research deal

New York, Jan 23, 2026, 15:42 EST — Regular session.

Shares of Voyager Technologies Inc (NYSE: VOYG) climbed roughly 6.4% to $36.80 in afternoon trading Friday, peaking at $38.84 earlier in the session. The stock kicked off the day at $35.64 and saw around 2.24 million shares change hands, hitting a low of $34.62.

This matters because Voyager remains a young, lightly covered stock in a market that favors straightforward narratives — new deals, fresh coverage, and a clear path to revenue. For names like this, just one new research note can attract momentum money, even if the actual impact takes months to show up in the numbers.

Voyager went public in June, with its shares more than doubling on their NYSE debut, pushing the company’s valuation to around $3.8 billion. The firm is also developing Starlab, a commercial space station project backed by NASA funding, according to Reuters at the time. 1

Friday saw a catalyst when Wedbush’s Dan Ives kicked off coverage with an Outperform rating and set a $46 price target. He described the company as “uniquely positioned” in defense, national security, space solutions, and space stations, Benzinga reported. 2

Just a day earlier, Voyager announced a deal with Space LiinTech to launch a drug-discovery payload to the International Space Station, pushing its role as a go-to mission manager for orbit-bound clients. “The most important breakthroughs in space-enabled medicine will come from consistent, high-fidelity access to orbit,” said Matt Magaña, Voyager’s president for Space, Defense & National Security. Space LiinTech’s Byungho Kim added that the collaboration aims to broaden “continuous space-based medicine research” over time. 3

Microgravity — the near-weightless state experienced in orbit — alters how materials take shape, affecting protein crystallization in particular. These crystals offer scientists a clearer view of molecular structures, aiding drug design and improvement here on Earth.

Voyager’s gains came amid a busy session for defense and government contractors. The stock climbed about 7% on Thursday following its ISS payload contract win, according to Investors.com. Booz Allen Hamilton also saw a boost after raising its annual earnings forecast. Analyst Louie DiPalma commented that Booz Allen seemed to be “getting its groove back.” 4

There are clear caveats. Voyager hasn’t revealed the financial details of the Space LiinTech deal or set a flight date. Plus, space research schedules often slip—launches get delayed, payloads miss their windows, and hardware sometimes fails to return.

Management is gearing up for a busy slate of investor events, with a presentation scheduled for the TD Cowen Aerospace & Defense Conference on Feb. 13, followed by the NYSE Space Summit on Feb. 23, the company announced. 5

Stock Market Today

Marvell (MRVL) stock slides nearly 4% even as FTC ends waiting period on Celestial AI deal
Previous Story

Marvell (MRVL) stock slides nearly 4% even as FTC ends waiting period on Celestial AI deal

Critical Metals (CRML) stock jumps 10% as Saudi rare-earth talks resurface in filing
Next Story

Critical Metals (CRML) stock jumps 10% as Saudi rare-earth talks resurface in filing

Go toTop